Effectiveness of ranibizumab intravitreal injections for exudative age-related macular degeneration treatment: 12-month outcomes

Medical Science Monitor

Volumn 17, Issue 9, 2011, Pages

  Figurska, Małgorzata ^a   Stankiewicz, Andrzej ^a  

^a MILITARY INSTITUTE OF MEDICINE   (Poland)

Author keywords

Central retinal thickness; Exudative AMD; Ranibizumab

Indexed keywords

RANIBIZUMAB;

ARTICLE; CENTRAL RETINAL THICKNESS; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; EXUDATIVE MACULAR DEGENERATION; FUNCTIONAL STATUS; HUMAN; RETINA; RETINA MACULA AGE RELATED DEGENERATION; TREATMENT OUTCOME; VISION; VISUAL ACUITY;

EID: 80054051500     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: 10.12659/MSM.881934     Document Type: Article

References (30)

1. Krejca M, Plewska A, Szmagala P et al: Outside stenting of the vein graft decreases VEGF-A expression and induces significant down-regulation of VEGFR-1 in the intimal and medial layers after the re-endotheliza-tion period. Med Sci Monit, 2010; 16(3): BR89-BR96
2. Czarkowska-Paczek B, Zendzian-Piotrowska M, Bartlomiejczyk I et al: Skeletal and heart muscle expression of PDGF-A and VEGF-A after an acute bout of exercise and endurance training in rats. Med Sci Monit, 2010; 16(5): BR147-BR53
3. Lowe J: RhuFav V2 inhibits VEGF-isoforms stimulated HUVEC proliferation. Ophthalmol Vis Sci, 2003; 44: 1828-29
4. Keyt BA, Nguyen HV, Berleau LT et al: Identification of vascular endo-thelial growth factor determinants for binding KDR and FLT-1 receptors. Generation of receptor-selective VEGF variants by site-directed mutagenesis. J Biol Chem, 1996; 271: 5638-46
5. Chen Y, Wiesmann C, Fuh G et al: Selection and analysis of an optimized anti-VEGF antibody: Crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol, 1999; 293: 865-81
6. Bakri SJ, Snyder MR, Reid JM et al: Pharmacokinetics of intravitreal ra-nibizumab (Lucentis). Ophthalmology, 2007; 114: 2179-82
7. Brown DM, Kaiser PK, Michels M et al: For the Anchor Study Group: Ranibizumab versus verteporfn for neovascular age-related macular degeneration. N Engl J Med., 2006; 355: 1432-44
8. Rosenfeld PJ, Brown DM, Heier JS et al: Ranibizumab for neovascular age-related macular degeneration. N Engl J Med., 2006; 355: 1419-31
9. Boyer DS, Antoszyk AN, Awh CC: Subgroup analisis of the MARINA study of ranibizumab in neovascular age-related macular degeneration. Ophthalmology, 2007; 114: 246-52
10. Raja MSA, Saldana M, Goldsmith C et al: Ranibizumab treatment for neovascular age-related macular degeneration in patients with good baseline visual acuity (better than 6/12): 12-month outcomes. Br J Ophthalmol, 2010; 94: 1543-45
11. Regillo CD, Brown DM, Abraham P: Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER Study year 1. Am J Ophthalmol, 2008; 145: 239-48
12. Lalwani GA, Rosenfeld PJ, Fung AE et al: A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO study. Am J Ophthalmol, 2009; 148: 43-53
13. Fung AE, Lalwani GA, Rosenfeld PJ: An optical coherence tomography - guided, variable dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration. Am J Ophthalmol, 2007; 143: 566-83
14. Meyer CH, Eter N, Holz FG: Ranibizumab in patients with subfove-al choroidal neovascularization secondary to age-related macular degeneration. Interim results from the SUSTAIN trial (abstract). Invest Ophthalmol Vis Sci, 2008; 49
15. Schmidt-Erfurth UM, Richard G, Augustin A et al: Guidance for the treatment of neovascular age-related macular degeneration. Acta Ophthalmol Scand, 2007; 85: 486-94
16. Kumar A, Sahni JN, Stangos AN et al: Effectiveness of ranibizumab for neovascular age-related macular degeneration using clinical-determined retreatment strategy. Br J Ophthalmol, 2011; 95: 530-33
17. Bandukwala T, Muni RH, Schwartz C et al: Effectiveness of intravitreal ranibizumab for the treatment of neovascular age-related macular degeneration in a Canadian retina practice: a retrospective review. Can J Ophthalmol, 2010; 45: 590-95
18. Cohen SY, Dubois L, Tadayoni R et al: Results of one year's treatment with ranibizumab for exudative age-related macular degeneration in a clinical setting. Am J Ophthalmol, 2009; 148: 409-13
19. Mitchell P, Korobelnik JF, Lanzetta P et al: Ranibizumab (Lucentis) in neovascular age-related macular degeneration: evidence from clinical trials. Br J Ophthalmol, 2010; 94: 2-13
20. Spaide RF: The as-needed treatment strategy for choroidal neovascu-larization: a feedback-based treatment system. Am J Ophthalmol, 2009; 148: 1-3
21. Spaide RF: Ranibizumab according to need: a treatment for age-related macular degeneration. Am J Ophthalmol, 2007; 143: 679-80
22. Rothenbuehler SP, Waeber D, Brinkmann ChK et al: Effect of ranibi-zumab in patients with subfoveal choroidal neovascularization attributable to age-related macular degeneration. Am J Ophthalmol, 2009; 147: 831-37
23. Arias L, Roman I, Masuet-Aumatell C et al: One-year results of a fexi-ble regimen with ranibizumab therapy in macular degeneration: relationship with the number of injections. Retina, 2011; X: 1-7
24. Kloos P, Bernasconi P, Estermann S et al: Visual acuity and magnifca-tion requirement after ranibizumab in patients with wet age-related macular degeneration. Klin Monbl Augenheilkd, 2008; 225: 385-91
25. Rotsos T, Patel PJ, Chen FK, Tufail A: Initial clinical experience of ra-nibizumab therapy for neovascular age-related macular degeneration. Clinical Ophthalmology, 2010: 4: 1271-75
26. Rosenfeld PJ, Moshfeghi AA, Puliafto CA: Optical coherence tomography fndings after an intravitreal injection of bevacizumab (Avastin) for noevascular age-related macular degeneration. Ophthalmic Surg Lasers Imaging, 2005; 36: 331-35
27. Kiss ChG, Geitzenauer W, Simader Ch et al: Evaluation of ranibizum-ab-induced changes in high-resolution opical coherence tomographic retinal morphology and their impact on visual function. Investigative Ophthalmology &Visual Science, 2009; 50: 2376-83
28. Dadgostar H, Ventura AA, Chung JY et al: Evaluation of injection frequency and visual acuity outcomes for ranibizumab monotherapy in exudative age-related macular degeneration. Ophthalmology, 2009; 116: 1740-47
29. Holz FG, Bindewald-Wittich A, Fleckenstein M et al: Progression of geographic atrophy and impact of fundus autofuorescence patterns in age-related macular degeneration. Am J Ophthalmol, 2007; 143: 463-72
30. Framme C, Panagakis G, Birngruber R: Effects on choroidal neovas-cularization after anti-VEGF upload using intravitreal ranibizumab, as determined by spectral domain-optical coherence tomography. Invest Ophthalmol Vis Sci, 2010; 51: 1671-76